Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release
- 1 September 1988
- journal article
- research article
- Published by Elsevier in Brain Research
- Vol. 460 (1) , 76-82
- https://doi.org/10.1016/0006-8993(88)90431-3
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- In Vivo Assessment of Dopamine and Norepinephrine Release in Rat Neocortex: Gas Chromatography‐Mass Spectrometry Measurement of 3‐Methoxytyramine and NormetanephrineJournal of Neurochemistry, 1987
- Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized ratNeurochemistry International, 1987
- Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosisBrain Research Reviews, 1986
- Further Studies on the Specificity of Proglumide as a Selective Cholecystokinin Antagonist in the Central Nervous SystemaAnnals of the New York Academy of Sciences, 1985
- Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patientsLife Sciences, 1985
- Cholecystokinin, dopamine and schizophreniaTrends in Pharmacological Sciences, 1984
- Effect of systemically administered caerulein on dopamine metabolism in rat brainBrain Research, 1984
- Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophreniaLife Sciences, 1983
- Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesionsLife Sciences, 1983
- Additional evidence that small amounts of a peptide can cross the blood-brain barrierPharmacology Biochemistry and Behavior, 1979